SK Biopharmaceuticals Co Ltd
KRX:326030

Watchlist Manager
SK Biopharmaceuticals Co Ltd Logo
SK Biopharmaceuticals Co Ltd
KRX:326030
Watchlist
Price: 104 500 KRW -0.19%
Market Cap: 8.2T KRW
Have any thoughts about
SK Biopharmaceuticals Co Ltd?
Write Note

SK Biopharmaceuticals Co Ltd
Accrued Liabilities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

SK Biopharmaceuticals Co Ltd
Accrued Liabilities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Accrued Liabilities CAGR 3Y CAGR 5Y CAGR 10Y
SK Biopharmaceuticals Co Ltd
KRX:326030
Accrued Liabilities
â‚©71.3B
CAGR 3-Years
25%
CAGR 5-Years
24%
CAGR 10-Years
N/A
Yuhan Corp
KRX:000100
Accrued Liabilities
â‚©37.5B
CAGR 3-Years
213%
CAGR 5-Years
36%
CAGR 10-Years
48%
Hanmi Science Co Ltd
KRX:008930
Accrued Liabilities
â‚©10.4B
CAGR 3-Years
17%
CAGR 5-Years
18%
CAGR 10-Years
12%
Hanmi Pharm Co Ltd
KRX:128940
Accrued Liabilities
â‚©52.7B
CAGR 3-Years
23%
CAGR 5-Years
11%
CAGR 10-Years
15%
S
Sam Chun Dang Pharm Co Ltd
KOSDAQ:000250
Accrued Liabilities
â‚©10.9B
CAGR 3-Years
9%
CAGR 5-Years
5%
CAGR 10-Years
14%
C
Celltrion Pharm Inc
KOSDAQ:068760
Accrued Liabilities
â‚©313m
CAGR 3-Years
-47%
CAGR 5-Years
-26%
CAGR 10-Years
-17%
No Stocks Found

SK Biopharmaceuticals Co Ltd
Glance View

Market Cap
8.2T KRW
Industry
Pharmaceuticals

SK Biopharmaceuticals Co., Ltd., a prominent player in the global biopharmaceutical industry, emerged as a distinctive entity out of one of South Korea's largest conglomerates, the SK Group. This pharmaceutical jewel draws its strength from innovation in the neurology and oncology sectors, fields brimming with both challenge and opportunity. At its core, SK Biopharmaceuticals is dedicated to the research, development, and commercialization of novel medications, with a significant focus on disorders impacting the central nervous system. Their pipeline and commercial activities revolve around cutting-edge therapies, such as the epilepsy drug Cenobamate, which has gained a foothold in both the U.S. and European markets. This drug, marketed under different names like Xcopri in the U.S., is a testament to the company's ability to leverage robust R&D capabilities into profitable products. Revenue generation for SK Biopharmaceuticals is predominantly driven by the sales of their innovative therapeutic solutions, as well as strategic collaborations with a network of global partners. They engage in a lifecycle approach where they not only develop and launch their own drugs but also license out their intellectual property, enhancing revenue streams through royalties and milestone payments. This hybrid model of sales and strategic partnerships showcases a deft mix of scientific prowess and commercial acumen, key to sustaining and propelling growth in a competitive market. Additionally, they continuously invest in research and alliances, aiming to expand their portfolio beyond existing successes, while targeting unmet medical needs that mirror their core strengths. This balanced approach positions SK Biopharmaceuticals not just as a standalone drugmaker, but as a dynamic player in shaping future therapies in their chosen niches.

Intrinsic Value
42 433.46 KRW
Overvaluation 59%
Intrinsic Value
Price

See Also

What is SK Biopharmaceuticals Co Ltd's Accrued Liabilities?
Accrued Liabilities
71.3B KRW

Based on the financial report for Dec 31, 2023, SK Biopharmaceuticals Co Ltd's Accrued Liabilities amounts to 71.3B KRW.

What is SK Biopharmaceuticals Co Ltd's Accrued Liabilities growth rate?
Accrued Liabilities CAGR 5Y
24%

Over the last year, the Accrued Liabilities growth was 30%. The average annual Accrued Liabilities growth rates for SK Biopharmaceuticals Co Ltd have been 25% over the past three years , 24% over the past five years .

Back to Top